{"preliminary_commentary":{"by_channel":{"bluesky_thread":16,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06053658\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT06053658","nct_id":"NCT06053658","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06053658. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Nivolumab by vein over about 60 minutes every 4 weeks (Day 1 of each cycle). Tivozanib tablets by mouth 1 time every day for 21 days (Days 1-21 of each cycle), and then no tablets on Days 22-28 of each cycle.","label":"Combination Tivozanib and Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["AVEO Pharmaceuticals, Inc."],"completion_date":{"date":"2028-11-01","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tivozanib","otherNames":["KRN 951","KRN-951","KRN951","UNII-172030934T","AV951","AV951 cpd"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo","BMS-936558"],"type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0","timeFrame":"through study completion; average of 1 year"}],"references":[],"start_date":{"date":"2024-01-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT06053658"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06053658"}